Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931709 · ClinicalTrials.gov registry record · NA
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
A NA study, sponsored by University of Washington.
- Terminated
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT01931709 is a NA study that was terminated before completion, run by University of Washington. The registered enrollment target is 35 participants.
The verdict
NCT01931709, a NA study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Interventions
- OTHER laboratory biomarker analysis
- RADIATION fludeoxyglucose F 18
- DEVICE positron emission tomography
- DEVICE dynamic contrast-enhanced magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-11 |
| Est. Completion | 2022-10-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01931709
The ClinicalTrials.gov registry entry for NCT01931709 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01931709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01931709 about?
NCT01931709 is a clinical study titled "FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer". This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after...
What is the current status of trial NCT01931709?
This trial is currently terminated. It is a NA study. The enrollment target is 35 participants. The study started on 2011-11. Estimated completion is 2022-10-26.
What interventions are being tested in trial NCT01931709?
The interventions under investigation include: laboratory biomarker analysis (OTHER), fludeoxyglucose F 18 (RADIATION), positron emission tomography (DEVICE), dynamic contrast-enhanced magnetic resonance imaging (DEVICE).
Who is sponsoring clinical trial NCT01931709?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.